Palvella Therapeutics (PVLA) Non-Current Deffered Revenue (2016 - 2023)

Palvella Therapeutics (PVLA) has 8 years of Non-Current Deffered Revenue data on file, last reported at $759000.0 in Q2 2023.

• Non-Current Deffered Revenue for Q2 2023 came in at $759000.0, changed N/A year-over-year; the trailing twelve-month figure through Jun 2023 was $759000.0 (changed N/A YoY), and the FY2022 annual result was $18.7 million, down 51.22% from the prior year.
• Non-Current Deffered Revenue declined to $759000.0 in Q2 2023 per PVLA's latest filing, from $11.7 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $59.7 million in Q1 2019 and troughed at $759000.0 in Q2 2023.
• A 5-year average of $35.6 million and a median of $37.8 million in 2020 frame the typical range for Non-Current Deffered Revenue.
• The sharpest annual moves came in 2021 and 2023: Non-Current Deffered Revenue soared 30.59% in 2021, then slumped 61.95% in 2023.
• A 5-year view of Non-Current Deffered Revenue shows it stood at $47.3 million in 2019, then fell by 24.03% to $35.9 million in 2020, then climbed by 6.97% to $38.4 million in 2021, then plunged by 51.22% to $18.7 million in 2022, then slumped by 95.95% to $759000.0 in 2023.
• Business Quant data shows PVLA's Non-Current Deffered Revenue at $759000.0 in Q2 2023, $11.7 million in Q1 2023, and $18.7 million in Q4 2022.